Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

Eenmalige plaatselijke inwendige bestraling voor de behandeling van patiŽnten met teruggekeerde prostaatkanker

- candidate number28527
- NTR NumberNTR7014
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR5-feb-2018
- Secondary IDs17-790 METC UMC Utrecht
- Public TitleEenmalige plaatselijke inwendige bestraling voor de behandeling van patiŽnten met teruggekeerde prostaatkanker
- Scientific TitlePRostatE Cancer MRI guided focal SalvagE high-dose-rate brachytherapy
- hypothesisThe purpose of this study is to evaluate toxicity and oncologic outcomes of MRI-guided focal salvage high-dose-rate brachytherapy (HDR-BT). In earlier studies, it was shown that focal salvage HDR-BT is feasible and results regarding toxicity are promising. Therefore, it is expected that focal salvage HDR-BT will be of benefit in patients with locally recurrent prostate cancer, with respect to both toxicity and tumor control.
- Healt Condition(s) or Problem(s) studiedProstate cancer, Brachytherapy
- Inclusion criteria- Age ≥18 years;
- Recurrence ≥2 years after primary radiotherapy treatment (LDR-BT or EBRT);
- PSA at time of salvage ≤20 ng/ml;
- PSA doubling time ≥9 months;
- Stage ≤T3b tumor (extra prostatic extension into the seminal vesicle(s));
- Acceptable toxicity of primary radiation treatment (IPSS <15);
- Concordance between PSMA-PET/CT and mp-MRI;
- Tumor location technically feasible for brachytherapy;
- Karnofsky score ≥70;
- Written informed consent;
- Fit for spinal anesthesia.
- Exclusion criteria- Distant metastases;
- Previous pelvic radiotherapy for another malignancy;
- Prior prostate treatment(s) like a recent transurethral resection of the prostate (TURP) (<6 months before focal salvage HDR treatment), HIFU or cryosurgery, except for radiotherapy;
- Contraindications for MRI;
- Severe toxicity from primary radiation treatment (IPSS >15);
- Anticoagulant administration continuously required, except for platelet aggregation inhibitors (for example Ascal/Persantin).
- mec approval receivedyes
- multicenter trialno
- randomisedno
- group[default]
- TypeSingle arm
- Studytypeintervention
- planned startdate 1-feb-2018
- planned closingdate1-feb-2031
- Target number of participants88
- InterventionsSingle fraction focal high-dose-rate brachytherapy to a dose of 19 Gray
- Primary outcomeTo investigate the occurrence of acute and late (>3 months) grade ≥3 GI and/or GU toxicity (aiming for <10% grade ≥3 toxicity) after MRI-guided focal salvage HDR-BT for locally recurrent prostate cancer.
- Secondary outcome- QoL;
- Biochemical disease free survival;
- Assessment on dose restrictions to prevent/reduce acute and late GU/GI toxicity;
- Evaluation of catheter shifts during focal salvage HDR-BT;
- Predictive factors for tumor control, to optimize patient selection.
- Timepoints4 weeks, 3 months, 6 months, 9 months, 1 year, 18 months, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years.
- Trial web site
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIES J.R.N. Voort van Zyp, van der
- Sponsor/Initiator University Medical Center Utrecht (UMCU)
- Funding
(Source(s) of Monetary or Material Support)
KWF Kankerbestrijding
- PublicationsNone
- Brief summaryDespite improvements in primary curative treatment modalities, prostate cancer recurrences are common. Various salvage treatments, such as radical prostatectomy, low-dose-rate brachytherapy, external beam radiotherapy, high intensity focused ultrasound and cryosurgery have been investigated. However, because of high failure and toxicity rates, these treatment modalities remain unpopular. High failure rates can be reduced by excluding patients with high risk characteristics for early distant metastases, for whom local salvage treatment has no benefit. High toxicity rates in whole-gland salvage irradiation therapies are caused by accumulation of dose to surrounding organs at risk. To reduce toxicity, focal therapy is warranted. With advancements in imaging modalities, determination of the exact tumor location has become possible, in addition to adequate exclusion of metastatic disease. Currently, the radiotherapy department in the University Medical Centre Utrecht has a 1.5T magnetic resonance imaging (MRI) high-dose-rate brachytherapy (HDR-BT) facility, allowing for optimal visualization during treatment. With this facility, focal treatment is possible by inserting catheters into the tumor under MRI-guidance. Due to the steep dose fall-off in brachytherapy, low radiation doses will be expected in the surrounding healthy tissues, while maximum dose can be applied to the tumor. Therefore, less toxicity to the organs at risk is expected, while tumor control is maintained. In earlier studies, it was shown that salvage HDR-BT is feasible. Moreover, results regarding toxicity are promising. Therefore, we expect that focal salvage MRI-guided HDR-BT will be of benefit in patients with locally recurrent prostate cancer.
- Main changes (audit trail)
- RECORD5-feb-2018 - 25-feb-2018

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar